公开(公告)号：US12098392B2

公开(公告)日：2024-09-24

申请号：US17458609

申请日：2021-08-27

申请人： Elixirgen Scientific, Inc

发明人： Minoru S. H. Ko

IPC分类号： C12N5/0793 ,  C07K14/00 ,  C12N5/071 ,  C12N5/074 ,  C12N5/077 ,  C12N5/0789 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86

CPC分类号： C12N5/0696 ,  C07K14/00 ,  C12N5/0619 ,  C12N5/0647 ,  C12N5/0658 ,  C12N5/067 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86 ,  C12N2015/8518 ,  C12N2310/14 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/08 ,  C12N2506/1323 ,  C12N2506/14 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2523/00 ,  C12N2760/18741 ,  C12N2760/18843 ,  C12N2800/107

摘要： In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being stable and highly efficient. The use of complicated culture steps is a large problem. In addition, there are also large problems in, for example, that the speed of cell differentiation is low, and hence long-period culture is required, and that the differentiation efficiency is low, and hence it is difficult to obtain a sufficient number of required cells. A method of inducing differentiation into a desired cell type, which induces differentiation within a short period of time and with high efficiency by the use of a Sendai virus vector capable of expressing a transcription factor, and as required, the use of a pluripotent stem cell in which an expression amount of a POU5F1 protein has been substantially removed or reduced, is provided.

公开(公告)号：US12018051B2

公开(公告)日：2024-06-25

申请号：US18162530

申请日：2023-01-31

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Peter Collins ,  Bo Liang ,  Shirin Munir ,  Anne Schaap Nutt ,  Ursula Buchholz ,  Natalie Mackow ,  Peter Kwong ,  Barney Graham ,  Jason McLellan

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/575 ,  A61K2039/70 ,  C07K2319/03 ,  C07K2319/033 ,  C12N2760/00022 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18641 ,  C12N2760/18643 ,  C12N2760/18671 ,  C12N2760/18722 ,  C12N2760/18734 ,  C12N2760/18741 ,  C12N2760/18743 ,  C12N2760/18771

摘要： Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.

公开(公告)号：US20180251735A1

公开(公告)日：2018-09-06

申请号：US15905982

申请日：2018-02-27

申请人： Elixirgen, LLC

发明人： Minoru S.H. Ko

IPC分类号： C12N5/074 ,  C12N15/85

CPC分类号： C12N5/0696 ,  C07K14/00 ,  C12N5/0619 ,  C12N5/0647 ,  C12N5/0658 ,  C12N5/067 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86 ,  C12N2015/8518 ,  C12N2310/14 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2506/08 ,  C12N2506/1323 ,  C12N2506/14 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2523/00 ,  C12N2760/18741 ,  C12N2760/18843 ,  C12N2800/107

摘要： In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being stable and highly efficient. The use of complicated culture steps is a large problem. In addition, there are also large problems in, for example, that the speed of cell differentiation is low, and hence long-period culture is required, and that the differentiation efficiency is low, and hence it is difficult to obtain a sufficient number of required cells. A method of inducing differentiation into a desired cell type, which induces differentiation within a short period of time and with high efficiency by the use of a Sendai virus vector capable of expressing a transcription factor, and as required, the use of a pluripotent stem cell in which an expression amount of a POU5F1 protein has been substantially removed or reduced, is provided.

公开(公告)号：US20240309053A1

公开(公告)日：2024-09-19

申请号：US18665309

申请日：2024-05-15

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Servic

发明人： Peter Collins ,  Bo Liang ,  Shirin Munir ,  Anne Schaap Nutt ,  Ursula Buchholz ,  Natalie Mackow ,  Peter Kwong ,  Barney Graham ,  Jason McLellan

IPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/575 ,  A61K2039/70 ,  C07K2319/03 ,  C07K2319/033 ,  C12N2760/00022 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18641 ,  C12N2760/18643 ,  C12N2760/18671 ,  C12N2760/18722 ,  C12N2760/18734 ,  C12N2760/18741 ,  C12N2760/18743 ,  C12N2760/18771

摘要： Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.

公开(公告)号：US20180312544A1

公开(公告)日：2018-11-01

申请号：US15545218

申请日：2016-01-20

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services

发明人： Peter Collins ,  Bo Liang ,  Shirin Munir ,  Anne Schaap Nutt ,  Ursula Buchholz ,  Natalie Mackow ,  Peter Kwong ,  Barney Graham ,  Jason McLellan

IPC分类号： C07K14/005 ,  A61P31/14 ,  A61K39/155 ,  A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/5256 ,  C07K2319/03 ,  C12N2760/18534 ,  C12N2760/18634 ,  C12N2760/18641 ,  C12N2760/18734 ,  C12N2760/18741

摘要： Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.